Psoriatic arthritis and COVID ‐19 pandemic: Consequences in medical treatment?
- 30 June 2020
- journal article
- research article
- Published by Wiley in Dermatologic Therapy
- Vol. 33 (5) , e13743
Abstract
The COVID‐19 pandemic has a strong negative impact on human society world‐wide. Patients with immune‐mediated disease may be prone to an increased risk of infection and/ or more severe course. We review the available data for patients with psoriatic arthritis (PSA) and systemic treatments. Current treatment options are summarized. Based upon the experience with COVID‐19 the following problems are addressed: (a) Can systemic treatment reduce comorbidities of PsA that are also comorbidities for COVID‐19? Does systemic medical treatment pose an increased risk of infection with SARS‐CoV‐2? Does systemic drug therapy have an impact on the risk of pulmonary fibrosis ‐ a factor with strong negative impact on COVID‐19 outcome? Small molecules, inhibitors of tumor necrosis factor alfa, interleukin and JAK inhibitors are considered. The data are inhomogeneous for the multiple drugs used in PsA. Although the risk for severe upper airway tract infections during clinical controlled trials was mostly in the range of placebo, these data have been obtained before the COVID‐19 pandemic and should be interpreted with caution. Some biologics demonstrated an anti‐fibrotic activity in vitro and in animal disease models. None of the biologics is indicated during an active infection with fever. In non‐symptomatic PsA patients, systemic drug therapy can be continued.Keywords
This publication has 49 references indexed in Scilit:
- Ustekinumab, an anti-IL-12/23 p40 monoclonal antibody, inhibits radiographic progression in patients with active psoriatic arthritis: results of an integrated analysis of radiographic data from the phase 3, multicentre, randomised, double-blind, placebo-controlled PSUMMIT-1 and PSUMMIT-2 trialsAnnals of the Rheumatic Diseases, 2014
- Efficacy and safety of the anti-IL-12/23 p40 monoclonal antibody, ustekinumab, in patients with active psoriatic arthritis despite conventional non-biological and biological anti-tumour necrosis factor therapy: 6-month and 1-year results of the phase 3, multicentre, double-blind, placebo-controlled, randomised PSUMMIT 2 trialAnnals of the Rheumatic Diseases, 2014
- Methotrexate and Lung Disease in Rheumatoid Arthritis: A Meta‐Analysis of Randomized Controlled TrialsArthritis & Rheumatology, 2014
- Meta-analysis of psoriasis, cardiovascular disease, and associated risk factorsJournal of the American Academy of Dermatology, 2013
- A randomized placebo-controlled trial of methotrexate in psoriatic arthritisRheumatology, 2012
- Blocking IL-17A Promotes the Resolution of Pulmonary Inflammation and Fibrosis Via TGF-β1–Dependent and –Independent MechanismsThe Journal of Immunology, 2011
- The risk of tuberculosis related to tumour necrosis factor antagonist therapies: a TBNET consensus statementEuropean Respiratory Journal, 2010
- Psoriatic arthritisDermatologic Therapy, 2010
- Sensitivity of the Classification of Psoriatic Arthritis Criteria in Early Psoriatic ArthritisThe Journal of Rheumatology, 2009
- Classification criteria for psoriatic arthritis: Development of new criteria from a large international studyArthritis & Rheumatism, 2006